Anthony Johnson, MD
Family Medicine · Valdosta, GANPI 1104186246
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,452 and has fallen 54.7% since, to $658 in 2025.
Across 291 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$742
- Johnson & Johnson$622
- Pfizer$463
- Novo Nordisk$450
- AbbVie$400
- Paratek Pharmaceuticals, Inc.$316
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,60399%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 38 | $742 |
| Johnson & Johnson | 30 | $622 |
| Pfizer | 28 | $463 |
| Novo Nordisk | 31 | $450 |
| AbbVie | 8 | $400 |
| Paratek Pharmaceuticals, Inc. | 6 | $316 |
| Boehringer Ingelheim | 10 | $262 |
| Merck | 21 | $237 |
| Otsuka America Pharmaceutical, Inc. | 6 | $223 |
| Lilly USA, LLC | 14 | $207 |
| Sanofi-aventis U.S. LLC | 15 | $199 |
| Axsome Therapeutics, Inc. | 7 | $173 |
| Amgen | 4 | $128 |
| Kowa Pharmaceuticals America, Inc. | 21 | $115 |
| Novartis | 5 | $109 |
| Abbott | 3 | $105 |
| Shield Therapeutics Inc | 3 | $104 |
| Bayer | 2 | $103 |
| Amarin Pharma, Inc. | 1 | $68 |
| GSK | 5 | $67 |
| AstraZeneca | 4 | $58 |
| Seqirus USA Inc | 3 | $48 |
| Nestle Healthcare Nutrition Inc. | 2 | $48 |
| Portola Pharmaceuticals, LLC | 1 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Exact Sciences | 2 | $44 |
| Eisai Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Boston Scientific | 1 | $28 |
| Almatica Pharma LLC | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Circassia Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,688 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $50,828 |
| JardianceEmpagliflozin | 36 | $42,348 |
| JanuviaSitagliptin Phosphate | 36 | $33,130 |
| OzempicSemaglutide | 26 | $22,899 |
| VascepaIcosapent Ethyl | 37 | $20,502 |
| Potassium Chloride | 188 | $4,938 |
| Atorvastatin Calcium | 395 | $3,452 |
| Levothyroxine Sodium | 182 | $2,154 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,853 |
| Amlodipine Besylate | 276 | $1,650 |
| Pantoprazole Sodium | 155 | $1,551 |
| Losartan Potassium | 156 | $1,465 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 21 | $1,307 |
| Pravastatin Sodium | 85 | $1,255 |
| Metoprolol Tartrate | 136 | $1,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $463 | $50,82866 claims |
| Boehringer IngelheimJardiance | $262 | $42,34836 claims |
| MerckJanuvia | $237 | $33,13036 claims |
| Novo NordiskOzempic | $450 | $22,89926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Valdosta
- Jeffrey KingsleyColumbus$404K
- Debbie HaginsSavannah$279K
- Yolanda WadeTyrone$233K
- Julian HutchinsWarrenton$222K
- Nadine Halliburton-FosterCumming$219K
- Contessa MetcalfeAtlanta$157K
- Elmore AlexanderStone Mountain$155K
- Bantwal BaligaColumbus$115K
- Avril CampbellFort Benning$108K
- Mitzi RubinMarietta$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.